Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8341269 | 0.89 | CYP4F2 (0.53) | MAOBCYP4F2CYP4A11HPGDRAB9A | |
| SCHEMBL755940 | 0.87 | LPL (0.54) | CYP4F2CYP4A11HPGDRAB9ALMNA | |
| SCHEMBL11752450 | 0.86 | KAT6A (0.52) | KAT6ACYP4F2CYP4A11 | |
| SCHEMBL27841873 | 0.86 | LPL (0.55) | CYP4F2CYP4A11 | |
| SCHEMBL11434969 | 0.86 | LPL (0.55) | CYP4F2CYP4A11 | |
| SCHEMBL30354557 | 0.85 | FOLH1 (0.61) | KAT6ARAB9A | |
| SCHEMBL9660695 | 0.85 | MAOB (0.58) | MAOBCYP4F2CYP4A11RAB9ANPC1 | |
| SCHEMBL8093173 | 0.85 | KAT6A (0.51) | KAT6ACYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL991080 | 0.85 | FOLH1 (0.61) | KAT6ARAB9A | |
| SCHEMBL12235066 | 0.85 | CYP4F2 (0.67) | MAOBCYP4F2CYP4A11MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376091-A1 | THIADIAZOLEAMIDE DERIVATIVES AND THEIR APPLICATIONS | ZHEJIANG UNIVERSITY (CN) | 2024-11-14 | — | — | US | disclosed |
| WO-2023238127-A1 | UBIQUITIN HIGH AFFINITY CYCLIC PEPTIDES AND METHODS OF USE THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2023-12-14 | — | — | WO | disclosed |
| EP-2509602-B1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-01-25 | — | — | EP | disclosed |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | ALIOS BIOPHARMA, INC. | 2016-02-18 | — | — | US | disclosed |
| US-8680270-B2 | Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8507727-B2 | Method for producing cyclohexyl alkyl ketones | MITSUBISHI GAS CHEMCIAL COMPANY, INC. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8309587-B2 | Piperidine and piperazine phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2479163-A1 | METHOD FOR PRODUCING CYCLOHEXYL ALKYL KETONES | Mitsubishi Gas Chemical Company, Inc. (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120178713-A1 | PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178970-A1 | METHOD FOR PRODUCING CYCLOHEXYL ALKYL KETONES | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20080125432-A1 | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family | DEVGEN NV (BE) | 2008-05-29 | — | — | US | disclosed |
| EP-1131290-B1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-6770650-B2 | CHEMOKINE RECEPTOR (CCR) ANTAGONISTS SUCH AS N-(1(S)-(4-(3,4-DICHLOROBENZYL)PIPERAZIN-1-YLMETHYL)-2-METHYLPROPYL)-4 -METHYLBENZAMIDE DIHYDROCHLORIDE SALT FOR TREATMENT OF ASTHMA | SYNTEX (U.S.A.) LLC | 2004-08-03 | — | — | US | disclosed |
| US-6342509-B1 | ANTIASTHMATICS, ANTIHISTAMINES OR BRONCHODIALATORS | SYNTEX (U.S.A.) LLC | 2002-01-29 | — | — | US | disclosed |
| US-6339087-B1 | FOR THERAPY OF INFLAMMATORY OR ALLERGIC DISEASES ARE SELECTED FROM ASTHMA, ALLERGIC RHINITIS, HYPERSENSITIVITY LUNG DISEASES, HYPERSENSITIVITY PNEUMONITIS, EOSINOPHILIC PNEUMONIAS, INFLAMMATORY BOWEL DISEASES, PSORIASIS, DERMATITIS | SYNTEX (U.S.A.) LLC | 2002-01-15 | — | — | US | disclosed |
| EP-0037187-B1 | SALTS AND AQUEOUS SOLUTIONS OF 6-METHYLAMINO-4-OXO-10-PROPYL-4H-PYRANO(3,2-G)-QUINOLINE-2,8-DI-CARBOXYLIC ACID AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH SALTS AND SOLUTIONS | FISONS plc (GB) | 1986-12-10 | — | — | EP | disclosed |
| EP-0108592-A1 | Leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1984-05-16 | — | — | EP | disclosed |
| US-4438277-A | Hydronaphthalene derivatives | SANKYO COMPANY, LIMITED (JP) | 1984-03-20 | — | — | US | disclosed |
| US-4361515-A | Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178713-A1 | PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, TRPA1, TRPV5 | KAT6A 1932/4885MAOB 2728/4885CYP4F2 3666/4885 |
| US-20240376091-A1 | THIADIAZOLEAMIDE DERIVATIVES AND THEIR APPLICATIONS | AR, GPER1, CYP19A1 | KAT6A 1252/4885MAOB 2054/4885CYP4F2 1004/4885 |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | MAVS, EIF2AK2, SARS1 | KAT6A 3278/4885MAOB 3969/4885CYP4F2 4240/4885 |
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | NQO1, SOD1, MDH2 | KAT6A 1685/4885MAOB 112/4885CYP4F2 351/4885 |
| US-20120178970-A1 | METHOD FOR PRODUCING CYCLOHEXYL ALKYL KETONES | HACL2, ALKBH3, HSD17B7 | KAT6A 426/4885MAOB 2770/4885CYP4F2 101/4885 |
| US-20080125432-A1 | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family | KCNA5, KCNA1, KCNJ2 | KAT6A 2266/4885MAOB 3466/4885CYP4F2 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.